Current status of glioma therapy
10.3760/cma.j.issn1008-6706.2021.10.036
- VernacularTitle:脑胶质瘤的治疗现状
- Author:
Mengting HAN
1
;
Zhenliang SUN
Author Information
1. 安徽理工大学附属奉贤医院中心实验室，上海 201499
- Keywords:
Brain neoplasms;
Glioma;
Surgery;
Signaling pathway;
Molecular targeted therapy;
Immunotherapy;
Treatment outcome;
Review
- From:
Chinese Journal of Primary Medicine and Pharmacy
2021;28(10):1596-1600
- CountryChina
- Language:Chinese
-
Abstract:
Gliomas are a group of refractory heterogeneous diseases. Gliomas even at the same pathological type and grade exhibit different outcomes after treatment. Therefore, glioma patients have obvious survival difference. The development of intraoperative auxiliary means has greatly contributed to surgical resection of glioma and remarkably increased therapeutic effects. The development of sensitizer realizes the combination of radiotherapy and chemotherapy and can improve the anti-tumor effects of oral temozolomide. Molecular markers and signal pathways involved in glioma, such as isocitrate dehydrogenase-1 mutation, epidermal growth factor amplification, high expression of vascular endothelial growth factor, Notch signal pathway, miRNA, etc. are involved in the occurrence and development of glioma and have an obvious impact on the proliferation, metastasis and invasion of glioma. They are potential molecular targets for the clinical treatment of glioma. Many different immunotherapy schemes are actively carried out in patients with glioma, but the unique tumor immune microenvironment of the central nervous system needs to be considered. This paper reviews the treatment progress of glioma in recent years.
